NASDAQ:EVOK

Evoke Pharma - EVOK Stock Forecast, Price & News

$2.31

-0.31 (-11.83%)

(As of 03/24/2023 08:51 PM ET)

Add

Compare

Today's Range: $2.25
▼
$2.52
50-Day Range: $2.31
▼
$5.75
52-Week Range: $1.37
▼
$16.80

Volume: 35,000 shs
Average Volume: 36,588 shs
Market Capitalization: $7.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Evoke Pharma (NASDAQ:EVOK) Stock

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

EVOK Stock News Headlines

March 25, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

March 24, 2023 | finance.yahoo.com

Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2022 Earnings Call Transcript

March 27, 2023 | Stansberry Research (Ad)

The gold catalyst we’ve waited for

If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.

March 24, 2023 | americanbankingnews.com

Evoke Pharma (NASDAQ:EVOK) Releases Earnings Results

March 23, 2023 | finance.yahoo.com

Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023

March 22, 2023 | finanznachrichten.de

Evoke Pharma, Inc.: Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

March 22, 2023 | benzinga.com

Glow Launches New Brand Identity to Underscore Its High-Performance, Technology-Driven Portfolio of Natural Ingredients

March 21, 2023 | marketwatch.com

Evoke Pharma Shares Up 4.8% on Higher 4Q Sales

March 27, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

March 21, 2023 | finance.yahoo.com

Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

March 21, 2023 | marketwatch.com

Gastroenterology Market: The Growing Trend 2030

March 20, 2023 | marketwatch.com

2023 Diabetic Gastroparesis Market Size, Trends, Growth, Share, Business Analysis, Key Players, Merger, Statistics, Competitive Landscape

March 20, 2023 | markets.businessinsider.com

Evoke Pharma is about to announce its earnings — here's what to expect

March 15, 2023 | finance.yahoo.com

Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023

February 23, 2023 | marketwatch.com

Diabetic Gastroparesis Market Future Trends Demand 2023, and Forecast to 2028

February 22, 2023 | marketwatch.com

Gastroenterology Market International Business Analysis, Development Outlook and Regional Strategies 2028

February 21, 2023 | finance.yahoo.com

Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session

February 18, 2023 | marketwatch.com

Gastroenterology Market 2023 : Incredible Possibilities, Growth Analysis and Forecast To 2028

January 30, 2023 | msn.com

Evoke stock rises on filing of dismissal in nasal spray Gimoti's patent infringement case

January 30, 2023 | finance.yahoo.com

Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

January 18, 2023 | finance.yahoo.com

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

January 5, 2023 | forbes.com

Evoke Pharma

December 14, 2022 | msn.com

Evoke Pharma's Return On Capital Employed Insights

December 7, 2022 | finance.yahoo.com

USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

November 30, 2022 | finance.yahoo.com

Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

November 12, 2022 | finance.yahoo.com

Evoke Pharma Third Quarter 2022 Earnings: Beats Expectations

November 10, 2022 | seekingalpha.com

Evoke Pharma, Inc. (EVOK) Q3 2022 Results - Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

EVOK Company Calendar

Last Earnings: 3/21/2023
Today: 3/26/2023
Next Earnings (Estimated): 5/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EVOK
CUSIP: N/A
CIK: 1403708
Web: www.evokepharma.com
Phone: (858) 345-1494
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.6803)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,540,000.00
Net Margins: -327.91%
Pretax Margin: -327.78%
Return on Equity: -175.51%
Return on Assets: -67.56%

Debt

Debt-to-Equity Ratio: 1.22
Current Ratio: 7.08
Quick Ratio: 6.94

Sales & Book Value

Annual Sales: $2.51 million
Price / Sales: 3.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.31 per share
Price / Book: 1.76

Miscellaneous

Outstanding Shares: 3,340,000
Free Float: 3,000,000
Market Cap: $7.72 million
Optionable: Not Optionable
Beta: 0.41

Key Executives

David A. Gonyer
Chief Executive Officer & Director

Matthew J. D'Onofrio
President, Chief Operating Officer & Secretary

Marilyn R. Carlson
Chief Medical Officer

Key Competitors

View All Competitors

EVOK Stock - Frequently Asked Questions

How have EVOK shares performed in 2023?: Evoke Pharma's stock was trading at $2.68 on January 1st, 2023. Since then, EVOK shares have decreased by 13.8% and is now trading at $2.31.
View the best growth stocks for 2023 here.
When is Evoke Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our EVOK earnings forecast.
How were Evoke Pharma's earnings last quarter?: Evoke Pharma, Inc. (NASDAQ:EVOK) announced its quarterly earnings results on Tuesday, March, 21st. The specialty pharmaceutical company reported ($0.53) earnings per share for the quarter. The specialty pharmaceutical company had revenue of $0.80 million for the quarter. Evoke Pharma had a negative trailing twelve-month return on equity of 175.51% and a negative net margin of 327.91%.
When did Evoke Pharma's stock split?: Shares of Evoke Pharma reverse split on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What other stocks do shareholders of Evoke Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).

What is Evoke Pharma's stock symbol?: Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."
Who are Evoke Pharma's major shareholders?: Evoke Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David A Gonyer and Matthew J D'onofrio.
View institutional ownership trends.
How do I buy shares of Evoke Pharma?: Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Evoke Pharma's stock price today?: One share of EVOK stock can currently be purchased for approximately $2.31.
How much money does Evoke Pharma make?: Evoke Pharma (NASDAQ:EVOK) has a market capitalization of $7.72 million and generates $2.51 million in revenue each year. The specialty pharmaceutical company earns $-8,540,000.00 in net income (profit) each year or ($2.6803) on an earnings per share basis.
How can I contact Evoke Pharma?: Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The official website for the company is www.evokepharma.com. The specialty pharmaceutical company can be reached via phone at (858) 345-1494 or via email at tbui@theruthgroup.com.

This page (NASDAQ:EVOK) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial